Abbott To Market Ditropan XL For Five Years: Deal Parallels Alza Merger
Executive Summary
Abbott's co-promotion agreements for Ditropan XL with Alza ensure that Abbott will continue to detail the once-daily overactive bladder treatment for the next five years even if the companies do not complete their proposed merger.
You may also be interested in...
Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem
Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.
Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem
Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.
Abbott Diagnostics Manufacturing Issues Could Decrease Alza Merger Value
Abbott's pending merger with Alza could give FDA leverage in discussions over quality control problems in Abbott's diagnostics business.